Benzinga | Oct 8, 2020 07:56AM EDT

Credit Suisse Reiterates Outperform on Mirati Therapeutics, Raises Price Target to $190

Credit Suisse analyst Evan Seigerman reiterates Mirati Therapeutics (NASDAQ:MRTX) with a Outperform and raises the price target from $140 to $190.